Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, o-desmethyltramadol, via activation of descending serotonergic pathways

Anesthesiology

Volumn 112, Issue 3, 2010, Pages 696-710

  Yanarates, Omer ^a   Dogrul, Ahmet ^b   Yildirim, Vedat ^a   Sahin, Altan ^c   Sizlan, Ali ^a   Seyrek, Melik ^b   Akgül, Özgür ^a   Kozak, Orhan ^b   Kurt, Ercan ^a   Aypar, Ulku ^c  

^a Department of Anesthesiology and Reanimation ^*  (United States)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3,N DIMETHYL N [1 METHYL 3 (4 METHYL 1 PIPERIDINYL)PROPYL]BENZENESULFONAMIDE; 5,7 DIHYDROXYTRYPTAMINE; KETANSERIN; O NORTRAMADOL; ONDANSETRON; SEROTONIN 7 RECEPTOR; TRAMADOL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL ANIMAL; MALE; METABOLITE; MOUSE; NOCICEPTION; NONHUMAN; PLANTAR INCISION TEST; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RADIANT HEAT TAIL FLICK TEST; SEROTONINERGIC SYSTEM;

EID: 77649175141     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181cd7920     Document Type: Article

References (52)

1. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43:879-923
2. Moore RA, McQuay HJ: Single-patient data meta-analysis of 3453 postoperative patients: Oral tramadol versus placebo, codeine and combination analgesics. Pain 1997; 69:287-294
3. Xie H, Dong ZQ, Ma F, Bauer WR, Wang X, Wu GC: Involvement of serotonin 2A receptors in the analgesic effect of tramadol in mono-arthritic rats. Brain Res 2008; 1210:76-83
4. Bamigbade TA, Davidson C, Langford RM, Stamford JA: Actions of tramadol, its enantiomers and principal metabolite, O desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 1997; 79:352-356
5. Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci 2007; 103:253-260
6. Tao Q, Stone DJ, Borenstein MR, Codd EE, Coogan TP, Desai-Krieger D, Liao S, Raffa RB: Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally. J Clin Pharm Ther 2002; 27:99-106
7. Campanero MA, García-Quetglas E, Sádaba B, Azanza JR: Simultaneous stereoselective analysis of tramadol and its primary phase I metabolites in plasma by liquid chroma-tography. Application to a pharmacokinetic study in humans. J Chromatogr A 2004; 1031:219-228
8. Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiede-bergs Arch Pharmacol 2000; 362:116-121
9. Raffa RB: Basic pharmacology relevant to drug abuse assessment: Tramadol as example. J Clin Pharm Ther 2008; 33:101-108
10. Shipton EA: Tramadol-present and future. Anaesth Intensive Care 2000; 28:363-374
11. Dayer P, Desmeules J, Collart L: Pharmacology of tramadol. Drugs 1997; 53(suppl 2):18-24
12. Arcioni R, Della Rocca M, Romanò S, Romano R, Pietropa-oli P, Gasparetto A: Ondansetron inhibits the analgesic effects of tramadol: A possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg 2002; 94:1553-1557
13. Barann M, Urban B, Stamer U, Dorner Z, Bönisch H, Brüss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: A possible mechanism for tramadol-induced early emesis. Eur J Pharmacol 2006; 531:54-58
14. Frink MC, Hennies HH, Englberger W, Hanrand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 1996; 46:1029-1036
15. Berrocoso E, Rojas-Corrales MO, Mico JA: Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice. Psychop-harmacology (Berl) 2006; 188:111-118
16. Oliva P, Aurilio C, Massimo F, Grella A, Maione S, Grella E, Scafuro M, Rossi F, Berrino L: The antinociceptive effect of tramadol in the formalin test is mediated by the serotoner-gic component. Eur J Pharmacol 2002; 445:179-185
17. De Witte JL, Schoenmaekers B, Sessler DI, Deloof T: The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 2001; 92: 1319-1321
18. Erhan E, Onal A, Kocabas S, Parlar A, Yegul I, Kosay S: Ondansetron does not block tramadol-induced analgesia in mice. Methods Find Exp Clin Pharmacol 2005; 27:629-632
19. Braz JM, Basbaum AI: Genetically expressed transneuronal tracer reveals direct and indirect serotonergic descending control circuits. J Comp Neurol 2008; 507:1990-2003
20. Millan MJ: Descending control of pain. Prog Neurobiol 2002; 66:355-474
21. Thomas DR, Atkinson PJ, Hastie PG, Midlemiss DN, Price GW: [3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues. Neuropharmacology 2002; 42:78-81
22. Dogrul A, Seyrek M: Systemic morphine produce antino-ciception mediated by spinal 5-HT7, but not 5-HT1A and 5-HT2 receptors in the spinal cord. Br J Pharmacol 2006; 149:498-505
23. Meuser T, Pietruck C, Gabriel A, Xie GX, Lim KJ, Pierce Palmer P: 5-HT7 receptors are involved in mediating 5-HTinduced activation of rat primary afferent neurons. Life Sci 2002; 71:2279-2289
24. Doly S, Fischer J, Brisorgueil MJ, Verge D, Conrath M: Pre-and postsynaptic localization of the 5-HT7 receptor in rat dorsal spinal cord: Immunocytochemical evidence. J Comp Neurol 2005; 26:256-269
25. Liu RJ, Zhang RX, Qiao JT, Dafny N: Interrelations of opioids with monoamines in descending inhibition of no-ciceptive transmission at the spinal level: An immunocy-tochemical study. Brain Res 1999; 830:183-190
26. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-110
27. Forbes IT, Dabbs S, Duckworth DM, Jennings AJ, King FD, Lovell PJ, Brown AM, Collin L, Hagan JJ, Middlemiss DN, Riley GJ, Thomas DR, Upton N: (R)-3, N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl] benzenesulfon-amide: The first selective 5-HT7 receptor antagonist. J Med Chem 1998; 41:655-657
28. Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, King FD, Middlemiss DN, Rahman SK, Saunders DV, Collin LL, Hagan JJ, Riley GJ, Thomas DR: A novel, potent, and selective 5-HT(7) antagonist:(R)-3-(2-(2-(4- methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970). J Med Chem 2000; 43:342-345
29. Pouzet B: SB-258741: A 5-HT7 receptor antagonist of potential clinical interest. CNS Drug Rev 2002; 8:90-100
30. Herndon JL, Ismaiel A, Ingher SP, Teitler M, Glennon RA: Ketanserine analogues: Structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem 1992; 35:4903-4910
31. Freeman AJ, Cunningham KT, Tyers MB: Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action. Anticancer Drugs 1992; 3:79-85
32. Hylden JL, Wilcox GL: Intrathecal morphine in mice: A new technique. Eur J Pharmacol 1980; 17:313-316
33. Pogattzki EM, Raja SN: A mouse model of incisional pain. Anesthesiology 2003; 99:1023-1027
34. Hung KC, Wu HE, Mizoguchi H, Leitermann R, Tseng LF: Intrathecal treatment with 6-hydroxydopamine or 5,7-di-hydroxytryptamine blocks the antinociception induced by endomorphin-1 and endomorphin-2 given intracerebrov-entricularly in the mouse. J Pharmacol Sci 2003; 93:299-306
35. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32:77-88
36. Romero G, Pujol M, Pauwels PJ: Reanalysis of constitu-tively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists. Naunyn Schmiedebergs Arch Pharmacol 2006; 374:31-39
37. Tallarida RJ, Murray RB: Manual of Pharmacologic Calculations with Computer Programs, 2nd edition. New York, Springer-Verlag, 1987, pp 26-31
38. Häring M, Marsicano G, Lutz B, Monory K: Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 2007; 146:1212-1219
39. Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006; 51:651-658
40. Girard P, Pansart Y, Coppe MC, Gillardin JM: Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat. Pharmacol Res 2001; 44:541-545
41. Wilder-Smith OHG, Arendt-Nielsen L: Postoperative hyper-algesia. Its clinical importance and relevance Anesthesiol-ogy 2006; 104:601-607
42. Zhao ZQ, Gao YJ, Sun YG, Zhao CS, Gereau RW, Chen ZF: Central serotonergic neurons are differentially required for opioid analgesia but not for morphine tolerance or morphine reward. Proc Natl Acad Sci USA 2007; 104: 14519-14524
43. Zhao ZQ, Chiechio S, Sun YG, Zhang KH, Zhao CS, Scott M, Johnson RL, Deneris ES, Renner KJ, Gereau RW, Chen ZF: Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci 2007; 27:6045-6053
44. Li JY, Wong CH, Huang EY, Lin YC, Chen YL, Tan PP, Chen JC: Modulations of spinal serotonin activity affect the development of morphine tolerance. Anesth Analg 2001; 92:1563-1568
45. Geranton MG, Fratto V, Tochiki KK, Hunt SP: Descending serotonergic controls regulate inflammation-induced mechanical hypersensitivity and methyl-CpG-binding protein 2 phosphorylation in the rat superficial dorsal horn. Mol Pain 2008; 4:35
46. Forbes IT, Douglas S, Gribble AD, Ife RJ, Lightfoot AP, Garner AE, Riley GJ, Jeffrey P, Stevens AJ, Stean TO, Thomas DR: SB-656104-A: A novel 5-HT7 receptor antagonist with improved in vivo properties. Bioorg Med Chem Lett 2002; 12:3341-3344
47. Kristensen JD, Hartvig P, Karlsten R, Gordh T, Halldin M: CSF and plasma pharmacokinetics of the NMDA receptor antagonist CPP after intrathecal, extradural and i.v. administration in anaesthetized pigs. Br J Anaesth 1995; 74:193-200
48. Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P: Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors Eur J Pharmacol 2004; 495:97-102
49. Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zama-nillo D, Vela JM: 5-HT7 receptor activation inhibits me-chanical hypersensitivity secondary to capsaicin sensitiza-tion in mice. Pain 2009; 141:239-247
50. Taylor BK, Basbaum AI: Systemic morphine-induced release of serotonin in the rostroventral medulla is not mimicked by morphine microinjection into the periaqueductal gray. J Neurochem 2003; 86:1129-1141
51. Driessen B, Reimann W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxy-tryptamine in the rat brain in vitro. Br J Pharmacol 1992; 105:147-151
52. Smith RA, Levine TR, Lachlan KA, Fediuk TA: The high cost of complexity in experimental design and data analysis: Type I and type II error rates in multiway ANOVA. Hum Commun Res 2002; 28:515-530